Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.58 |
| ▸ | RAB9A | P51151 | 12/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL1764260 | 0.98 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| Hydrochloric Acid SCHEMBL3940287 | 0.98 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| Hydrochloric Acid SCHEMBL5730550 | 0.98 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| Hydrochloric Acid SCHEMBL22366427 | 0.96 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| SCHEMBL23530634 | 0.85 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| SCHEMBL2732396 | 0.85 | PDE10A (0.59) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| Hydrochloric Acid SCHEMBL12478474 | 0.84 | PDE10A (0.57) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| Hydrochloric Acid SCHEMBL948504 | 0.84 | PDE10A (0.57) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| SCHEMBL9570362 | 0.81 | KDM4E (0.56) | NPC1RAB9ASMN1; SMN2TP53MAPK1 | |
| SCHEMBL9043267 | 0.81 | RAB9A (0.55) | NPC1RAB9ASMN1; SMN2TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-113874080-B | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-112739366-B | Oral formulations of kappa opioid receptor agonists | 卡拉治疗学股份有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4240736-A1 | PPAR GAMMA MODULATORS AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2023-09-13 | — | — | EP | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2011097607-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREEN FOR ANTI-VIRAL AGENT | SOUTHERN RESEARCH INSTITUTE (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| US-6863647-B2 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2005-03-08 | — | — | US | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
| WO-2002066477-A2 | IMIDAZOPYRIDINES | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | NPC1 2685/4885RAB9A 2674/4885SMN1; SMN2 2448/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | NPC1 720/4885RAB9A 2521/4885SMN1; SMN2 2060/4885 |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | NPC1 3814/4885RAB9A 2672/4885SMN1; SMN2 959/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | NPC1 3473/4885RAB9A 3112/4885SMN1; SMN2 4705/4885 |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | NPC1 408/4885RAB9A 2907/4885SMN1; SMN2 4286/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | NPC1 2685/4885RAB9A 2674/4885SMN1; SMN2 2448/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | NPC1 550/4885RAB9A 2747/4885SMN1; SMN2 3901/4885 |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | P2RX3, P2RX2, P2RX5 | NPC1 2435/4885RAB9A 3635/4885SMN1; SMN2 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.